The pathology and genetics of metastatic pancreatic cancer

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 3, 2009, Pages 413-422

  Yachida, Shinichi ^a   Lacobuzio Donahue, Christine A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A2; SMAD4 PROTEIN; SONIC HEDGEHOG PROTEIN;

ANTIBODY LABELING; DIFFERENTIAL DIAGNOSIS; DPC4 GENE; GENE; HUMAN; LIVER CANCER; LUNG CANCER; METASTASIS; MKK4 GENE; OVARY CANCER; PANCREAS CANCER; PROTEIN EXPRESSION; REVIEW;

DIAGNOSIS, DIFFERENTIAL; HUMANS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RECEPTOR, EPHA2; SMAD4 PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 62249108705     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
3. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199-1210, discussion 1210-1211.
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2007;25:1960-1966.
5. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157-188.
6. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-799.
7. PawlikTM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11:1057-1077.
8. Verslype C, Van Cutsem E, Dicato M, et al. The management of pancreatic cancer: current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007;18(suppl 7):vii1-vii10.
9. Kamisawa T, Isawa T, Koike M, Tsuruta K, Okamoto A. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 1995;11:345-349.
10. Mao C, Domenico DR, Kim K, Hanson DJ, Howard JM. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma: findings of 154 autopsies. Arch Surg. 1995;130:125-134.
11. Embuscado EE, Laheru D, Ricci F, et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther. 2005;4:548-554.
12. Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008;132:931-939.
13. Amikura K, Kobari M, Matsuno S. The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreatol. 1995;17:139-146.
14. Vogel I, Kruger U, Marxsen J, et al. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. Clin Cancer Res. 1999;5:593-599.
15. Roder JD, Thorban S, Pantel K, Siewert JR. Micrometastases in bone marrow: prognostic indicators for pancreatic cancer. World J Surg. 1999;23:888-891.
16. Yachida S, Fukushima N, Sakamoto M, Matsuno Y, KosugeT, Hirohashi S. Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg. 2002;89:573-578.
17. Nakahashi C, Oda T, Kinoshita T, et al. The impact of liver metastasis on mortality in patients initially diagnosed with locally advanced or resectable pancreatic cancer. Int J Gastrointest Cancer. 2003;33:155-164.
18. Hishinuma S, Ogata Y, Matsui J, Ozawa I. Results of surgery and adjuvant radiotherapy for pancreatic cancer. J Hepatobiliary Pancreat Surg. 1998;5:143-150.
19. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. Dpc4 gene status of the primary carcinoma correlates with local versus metastatic failure in patients with pancreatic cancer. J Clin Oncol. 2009. In press.
20. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72:2118-2123.
21. Greer SE, Pipas JM, Sutton JE, et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg. 2008;206:451-457.
22. Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138:618-628, discussion 628-630.
23. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236:355-366, discussion 366-358.
24. Winter JM, Ting AH, Vilardell F, et al. Absence of e-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 2008;14:412-418.
25. Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol. 2007;9:1000-1004.
26. Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlich D, Menke A. TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci. 2005;118:4901-4912.
27. Deckers M, van Dinther M, Buijs J, et al. The tumor suppressor smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006;66:2202-2209.
28. Terayama N, Terada T, Nakanuma Y. Histologic growth patterns of metastatic carcinomas of the liver. Jpn J Clin Oncol. 1996;26:24-29.
29. Yamamoto J, Saiura A, Koga R, et al. Surgical treatment for metastatic malignancies: nonanatomical resection of liver metastasis: indications and outcomes. Int J Clin Oncol. 2005;10:97-102.
30. Allaire GS, Rabin L, Ishak KG, Sesterhenn IA. Bile ductadenoma: a study of 152 cases. Am J Surg Pathol. 1988;12:708-715.
31. Govindarajan S, Peters RL. The bile duct adenoma: a lesion distinct from Meyenburg complex. Arch Pathol Lab Med. 1984;108:922-924.
32. Shah JP, Goldsmith HS, Huvos AG. Hamartomas of the liver. Surgery. 1970;68:778-782.
33. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol. 2005;29:381-389.
34. Hruban RH, Sturm PD, Slebos RJ, et al. Can k-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver?: a molecular analysis of 101 liver lesions from 93 patients. Am J Pathol. 1997;151:943-949.
35. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308-321.
36. Argani P, Shaukat A, Kaushal M, et al. Differing rates of loss of dpc4 expression and ofp53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer. 2001;91:1332-1341.
37. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393:535-545.
38. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol. 2008;9:649-656.
39. Karanjawala ZE, Hruban RH, Iacobuzio-Donahue CA. Metastatic pancreatic cancer to the lung: a potential mimicker of primary bronchioalveolar carcinoma of the lung. Mod Pathol. 2008;21:307A.
40. Young RH. From Krukenbergto today: the ever present problems posed by metastatic tumors in the ovary: part II. Adv Anat Pathol. 2007;14:149-177.
41. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985-993.
42. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, dpc4, and muc5ac in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol. 2002;21:391-400.
43. Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differ entiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol. 2005;24:67-72.
44. Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, et al. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res. 2004;64:871-875.
45. Calhoun ES, Hucl T, Gallmeier E, et al. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res. 2006;66:7920-7928.
46. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (mts1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8:27-32.
47. Hahn SA, Schutte M, Hoque AT, et al. Dpc4, acandidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-353.
48. Redston MS, Caldas C, Seymour AB, et al. P53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994;54:3025-3033.
49. Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support mkk4 as a genetically targeted tumor suppressor gene. Cancer Res. 1998;58:2339-2342.
50. Goggins M, Schutte M, Lu J, et al. Germline brca2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360-5364.
51. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-2972.
52. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol. 2002;161:1541-1547.
53. Aguirre AJ, Brennan C, Bailey G, et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A. 2004;101:9067-9072.
54. Nowak NJ, Gaile D, Conroy JM, et al. Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet. 2005;161:36-50.
55. Bashyam MD, Bair R, Kim YH, et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia. 2005;7:556-562.
56. Mahlamaki EH, Kauraniemi P, Monni O, Wolf M, Hautaniemi S, Kallioniemi A. High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia. 2004;6:432-439.
57. Heidenblad M, Schoenmakers EF, Jonson T, et al. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res. 2004;64:3052-3059.
58. Heidenblad M, Lindgren D, Veltman JA, et al. Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications. Oncogene. 2005;24:1794-1801.
59. Hahn SA, Seymour AB, Hoque AT, et al. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res. 1995;55:4670-4675.
60. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-1037.
61. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highlyexpressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003;63:8614-8622.
62. Kranenburg O. The kras oncogene: past, present, and future. Biochim Biophys Acta. 2005;1756:81-82.
63. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. Kras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988;16:7773-7782.
64. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas: astudyof82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143:545-554.
65. Moskaluk CA, Hruban RH, Kern SE. P16 and k-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 1997;57:2140-2143.
66. Luttges J, Schlehe B, Menke MA, Vogel I, Henne-Bruns D, Kloppel G. The k-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer. 1999;85:1703-1710.
67. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
68. Ruggeri BA, Huang L, Berger D, et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/waf-1 genes in sporadic and familial lesions. Cancer. 1997;79:700-716.
69. Weyrer K, Feichtinger H, Haun M, et al. P53, ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest. 1996;74:279-289.
70. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24:5764-5774.
71. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of dpc4 in pancreatic intraepithelial neoplasia: evidence that dpc4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002-2006.
72. Tascilar M, Skinner HG, Rosty C, et al. The smad4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001;7:4115-4121.
73. Biankin AV, Morey AL, Lee CS, et al. Dpc4/smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol. 2002;20:4531-4542.
74. Sanchez I, Hughes RT, Mayer BJ, et al. Role of sapk/erk kinase-1 in the stress-activated pathway regulating transcription factor c-jun. Nature. 1994;372:794-798.
75. Xin W, Yun KJ, Ricci F, et al. Map2k4/mkk4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res. 2004;10:8516-8520.
76. Yamada SD, Hickson JA, Hrobowski Y, et al. Mitogen-activated protein kinase kinase 4 (mkk4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 2002;62:6717-6723.
77. Cunningham SC, Gallmeier E, Hucl T, et al. Targeted deletion of mkk4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res. 2006;66:5560-5564.
78. Cunningham SC, Gallmeier E, Hucl T, et al. Theoretical proposal: allele dosage of map2k4/mkk4 could rationalize frequent 17p loss in diverse human cancers. Cell Cycle. 2006;5:1090-1093.
79. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005;6:462-475.
80. Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. Differential regulation of epha2 in normal and malignant cells. Am J Pathol. 2003;162:1037-1042.
81. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Epha2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene. 2004;23:1448-1456.
82. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Ligation of epha2 by ephrin a1-fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun. 2004;320:1096-1102.
83. Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA. Patterns of epha2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis. 2006;23:357-365.
84. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the epha2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 2002;62:2840-2847.
85. Missiaglia E, Blaveri E, Terris B, et al. Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer. 2004;112:100-112.
86. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002;62:819-826.
87. Grutzmann R, Pilarsky C, Ammerpohl O, et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia. 2004;6:611-622.
88. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene. 2002;21:4587-4594.
89. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63:2649-2657.
90. Campagna D, Cope L, Lakkur SS, Henderson CM, Laheru D, Iacobuzio-Donahue CA. Gene expression profiles associated with advanced pancreatic cancer. Int J Clin Exp Pathol. 2008;1:32-43.
91. Hurlin PJ, Huang J. The max-interacting transcription factor network. Semin Cancer Biol. 2006;16:265-274.
92. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-myc target gene network. Semin Cancer Biol. 2006;16:253-264.
93. Corn PG, Ricci MS, Scata KA, et al. Mxi1 is induced by hypoxia in a hif-1-dependent manner and protects cells from c-myc-induced apoptosis. Cancer Biol Ther. 2005;4:1285-1294.
94. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. C-myc activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol. 2002;15:462-469.
95. Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas. 2004;29:193-203.
96. Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N, Nakamura M. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in nod/scid/gammacnull (nog) mice. Int J Oncol. 2007;31:741-751.
97. Tarbe N, Evtimova V, Burtscher H, Jarsch M, Alves F, Weidle UH. Transcriptional profiling of cell lines derived from an orthotopic pancreatic tumor model reveals metastasis-associated genes. Anticancer Res. 2001;21:3221-3228.
98. Niedergethmann M, Alves F, Neff JK, et al. Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic scid mouse model. Br J Cancer. 2007;97:1432-1440.
99. Nomura H, Nishimori H, Yasoshima T, et al. A new liver metastatic and peritoneal dissemination model established from the same human pancreatic cancer cell line: analysis using cdna macroarray. Clin Exp Metastasis. 2002;19:391-399.
100. Kim SK, Hebrok M, Melton DA. Notochord to endoderm signaling is required for pancreas development. Development. 1997;124:4243-4252.
101. Hebrok M, Kim SK, Melton DA. Notochord repression of endodermal sonic hedgehog permits pancreas development. Genes Dev. 1998;12:1705-1713.
102. Riobo NA, Lu K, Emerson CP Jr. Hedgehog signal transduction: signal integration and cross talk in development and cancer. Cell Cycle. 2006;5:1612-1615.
103. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432:324-331.
104. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425:846-851.
105. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425:851-856.
106. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67:2187-2196.